July 13, 2020
NG Biotech has obtained the Rapid Diagnostic Orientation Test (TROD) label for its NG-Test® IgG-IgM COVID-19 serological test following the ministerial decree of the 11th of July.
With this TROD status, private doctors and pharmacists can now use this rapid serological test for the detection of antibodies (IgG-IgM) against SARS-CoV-2.
NG Biotech provides pharmacists and general practitioners with a unique “all-in-one” test that responds particularly well to the expectations of primary care healthcare professionals with regard to TROD: without manipulation, it is practical, hygienic, very easy to use and reliable. Blood collection is perfectly controlled (the volume taken is always the same) and secure. It makes it possible, from a simple drop of blood taken at the fingertip and in fifteen minutes, to search for the possible presence of antibodies (IgG / IgM) directed against the virus of COVID-19.
Claimed for several weeks by pharmacists and liberal doctors to meet the demands of French people wishing to know their immune status, this test is an important tool in the strategy of prevention and epidemiological investigation, in accordance with the recommendations of the High Authority for Health (HAS).
Proven use in hospitals and the military
Validated by the Institut Pasteur and referenced by the HAS, NG-Test® IgG-IgM COVID-19 was previously distributed in hospitals and the military. As early as April, NG Biotech obtained orders from the AP-HP and the Rennes University Hospital which is currently carrying out a serological prevalence study among 13,000 caregivers.
Our test is also the subject of a contract with the Ministry of the Armed Forces and the General Directorate of Health for distribution to the Regional Health Agencies.
It has been the subject of 8 clinical evaluations and several international publications.
